From the Chief Executive
One area where it has traditionally been difficult for the medicines industry has been in developing medicines for neglected tropical diseases, such as chagas disease, dengue, leprosy, rabies , yaws, guinea-worm disease, and trachoma.
These diseases have generally people in some of the poorest countries in the world.
Historically, the problem for companies is that it is difficult to make investments in developing treatments for such diseases commercially viable. The normal commercial model of developing a medicine, where it costs around $1.5 billion and 15 years to develop, has not worked as well for developing treatments for these types of diseases. However, over the last decade…
News and Updates
Medicines industry economic impact up by $1bn - 28 December
The Australian medicines industry’s contribution to the economy grew by an estimated $1 billion year-on-year, and its turnover rose by almost $400 million according to a new industry “Facts Book” published today.
Retirement of Medicines Australia chairman Will Delaat - 20 December
Medicines Australia chairman Will Delaat announced today that he will retire from the position in February 2012.
Mr Delaat has served on the board of Medicines Australia since 1998 and has been chairman since 2008. He was previously chairman between 2003 and 2005.
MoU delivers Government substantial PBS savings - 20 December
Substantial price cuts to medicines on the Pharmaceutical Benefits Scheme announced by the Government will yield taxpayers major savings that will keep the PBS affordable, while providing the Government with the capacity to list new medicines in the future.
Medicines Australia welcomes Cabinet appointments - 12 December
Medicines Australia congratulates outgoing Minister for Health and Ageing Nicola Roxon and outgoing Innovation and Industry Minister Senator Kim Carr on their contributions to their respective portfolios over the past four years.
Spotlight
